Source 1primary paper2026MED
Toolkit/aptamer-functionalized lipid nanoparticles
aptamer-functionalized lipid nanoparticles
Also known as: aptamer-functionalized lipid nanoparticles (LNPs), aptamer-functionalized LNPs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Here, we developed aptamer-functionalized lipid nanoparticles (LNPs) for targeted mRNA delivery to CD4+ T cells.
Usefulness & Problems
No literature-backed usefulness or problem-fit explainer has been materialized for this record yet.
Published Workflows
Objective: Develop aptamer-functionalized LNPs for targeted mRNA delivery to CD4+ T cells and evaluate their binding, in vitro transfection, in vivo biodistribution, and safety.
Why it works: The workflow combines CD4-binding aptamers with LNP mRNA carriers so that receptor-directed binding can improve delivery specificity to CD4+ T cells while preserving a tunable nanoparticle formulation for in vivo use.
aptamer-mediated binding to CD4LNP-mediated mRNA deliveryaptamer functionalization of LNPsAI-guided aptamer designphysiochemical characterizationin vitro transfection testingin vivo biodistribution testingsafety evaluation
Stages
- 1.Aptamer generation and LNP design(library_design)
This stage provides targeting ligands for constructing CD4-directed LNPs.
Selection: Use a validated CD4-binding aptamer and novel aptamers generated by a transformer-based AI language model for CD4-targeted LNP functionalization.
- 2.LNP formulation and physicochemical characterization(library_build)
This stage creates the aptamer-LNP formulations to be tested and characterizes their physical properties before biological evaluation.
Selection: Formulate LNPs with SM102 or MC3 and conjugate aptamers at controlled densities.
- 3.Binding assessment(functional_characterization)
This stage tests whether aptamer-functionalized LNPs engage the intended CD4 target before downstream delivery studies.
Selection: Assess selective binding to recombinant CD4.
- 4.In vitro transfection assessment(secondary_characterization)
This stage tests whether target binding translates into selective cellular delivery in a cell-based assay before in vivo studies.
Selection: Assess enhanced transfection of CD4+ versus CD4- T cells in vitro.
- 5.In vivo biodistribution and safety evaluation(confirmatory_validation)
This stage confirms whether the targeted formulations retain delivery enrichment and suitable safety in vivo.
Selection: Assess enrichment of mRNA delivery to immune-rich tissues and evaluate safety.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Techniques
Computational DesignTarget processes
No target processes tagged yet.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Aptamer-functionalized LNPs showed selective nanomolar binding to recombinant CD4.
binding affinity range nanomolar
Aptamer-functionalized LNPs significantly enriched mRNA delivery to immune-rich tissues in vivo, with up to 70-fold spleen signal enhancement for SM102 formulations compared with non-targeted controls.
spleen signal enhancement 70 fold
The paper presents aptamer-functionalized LNPs augmented by AI-guided aptamer design as a tunable, non-immunogenic platform for in vivo T-cell engineering.
Aptamer-functionalized LNPs maintained suitable safety profiles in the reported evaluations.
The study developed aptamer-functionalized lipid nanoparticles for targeted mRNA delivery to CD4+ T cells.
Aptamer-functionalized LNPs achieved enhanced transfection of CD4+ versus CD4- T cells in vitro.
Approval Evidence
1 source6 linked approval claimsfirst-pass slug aptamer-functionalized-lipid-nanoparticles
Here, we developed aptamer-functionalized lipid nanoparticles (LNPs) for targeted mRNA delivery to CD4+ T cells.
Source:
binding performancesupports
Aptamer-functionalized LNPs showed selective nanomolar binding to recombinant CD4.
Source:
biodistribution enrichmentsupports
Aptamer-functionalized LNPs significantly enriched mRNA delivery to immune-rich tissues in vivo, with up to 70-fold spleen signal enhancement for SM102 formulations compared with non-targeted controls.
Source:
platform characterizationsupports
The paper presents aptamer-functionalized LNPs augmented by AI-guided aptamer design as a tunable, non-immunogenic platform for in vivo T-cell engineering.
Source:
safety profilesupports
Aptamer-functionalized LNPs maintained suitable safety profiles in the reported evaluations.
Source:
tool developmentsupports
The study developed aptamer-functionalized lipid nanoparticles for targeted mRNA delivery to CD4+ T cells.
Source:
transfection selectivitysupports
Aptamer-functionalized LNPs achieved enhanced transfection of CD4+ versus CD4- T cells in vitro.
Source:
Comparisons
No literature-backed comparison notes have been materialized for this record yet.
Ranked Citations
- 1.